Literature DB >> 15672382

Mutator phenotype in cancer: timing and perspectives.

Jason H Bielas1, Lawrence A Loeb.   

Abstract

Normal human cells replicate their DNA with exceptional accuracy. During every division cycle, each daughter cell receives a full and accurate complement of genetic information. It has been estimated that approximately one error occurs during DNA replication for each 10(9) to 10(10) nucleotides polymerized. Stem cells, the cells that are progenitors of cancer, may replicate their genes even more accurately. In contrast, the malignant cells that constitute a tumor are markedly heterogeneous and exhibit multiple chromosomal abnormalities and alterations in the nucleotide sequence of DNA. To account for the disparity between the rarity of mutations in normal cells and the large numbers of mutations present in cancer, we initially hypothesized that during tumor progression, cancer cells must exhibit a mutator phenotype. In this perspective, we summarize the evidence supporting a mutator phenotype in human cancer, analyze recent measurements of mutations in human cancer, consider the timing for the expression of a mutator phenotype, and focus on the important consequences of large numbers of random mutations in human tumors.

Entities:  

Mesh:

Year:  2005        PMID: 15672382     DOI: 10.1002/em.20111

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  19 in total

1.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

2.  An editing-defective aminoacyl-tRNA synthetase is mutagenic in aging bacteria via the SOS response.

Authors:  Jamie M Bacher; Paul Schimmel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-30       Impact factor: 11.205

3.  Pools and Pols: Mechanism of a mutator phenotype.

Authors:  Christal D Sohl; Sreerupa Ray; Joann B Sweasy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-30       Impact factor: 11.205

4.  The human gastric cancer-associated DNA polymerase β variant D160N is a mutator that induces cellular transformation.

Authors:  Katherine A Donigan; Suzanne E Hile; Kristin A Eckert; Joann B Sweasy
Journal:  DNA Repair (Amst)       Date:  2012-02-15

5.  Conditional coalescent trees with two mutation rates and their application to genomic instability.

Authors:  Mathieu Emily; Olivier François
Journal:  Genetics       Date:  2005-12-30       Impact factor: 4.562

6.  Nuclear reorganization of DNA mismatch repair proteins in response to DNA damage.

Authors:  Adam S Mastrocola; Christopher D Heinen
Journal:  DNA Repair (Amst)       Date:  2009-12-08

Review 7.  Moderate alcohol consumption and breast cancer in women: from epidemiology to mechanisms and interventions.

Authors:  Philip J Brooks; Samir Zakhari
Journal:  Alcohol Clin Exp Res       Date:  2012-10-16       Impact factor: 3.455

8.  Transcription errors induce proteotoxic stress and shorten cellular lifespan.

Authors:  Marc Vermulst; Ashley S Denney; Michael J Lang; Chao-Wei Hung; Stephanie Moore; M Arthur Moseley; Arthur M Mosely; J Will Thompson; William J Thompson; Victoria Madden; Jacob Gauer; Katie J Wolfe; Daniel W Summers; Jennifer Schleit; George L Sutphin; Suraiya Haroon; Agnes Holczbauer; Joanne Caine; James Jorgenson; Douglas Cyr; Matt Kaeberlein; Jeffrey N Strathern; Mara C Duncan; Dorothy A Erie
Journal:  Nat Commun       Date:  2015-08-25       Impact factor: 14.919

9.  Human T-cell leukemia virus type 1 tax attenuates the ATM-mediated cellular DNA damage response.

Authors:  Chandtip Chandhasin; Razvan I Ducu; Elijahu Berkovich; Michael B Kastan; Susan J Marriott
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

10.  The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer.

Authors:  Isabel Alvarado-Cruz; Rithy Meas; Sesha Lakshmi Arathi Paluri; Kelly Estelle Wheeler Carufe; Mohammed Khan; Joann Balazs Sweasy
Journal:  Mutagenesis       Date:  2020-02-13       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.